Mymetics (MYMX) Stock Overview
Engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MYMX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Mymetics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0003 |
| 52 Week High | US$0.0003 |
| 52 Week Low | US$0.0003 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| MYMX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 3.3% | 3.1% |
| 1Y | n/a | 26.7% | 14.6% |
Return vs Industry: Insufficient data to determine how MYMX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how MYMX performed against the US Market.
Price Volatility
| MYMX volatility | |
|---|---|
| MYMX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MYMX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine MYMX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | n/a | www.mymetics.com |
Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company’s product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, malaria, and chikungunya. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines.
Mymetics Corporation Fundamentals Summary
| MYMX fundamental statistics | |
|---|---|
| Market cap | US$45.00 |
| Earnings (TTM) | -US$13.63m |
| Revenue (TTM) | US$627.87k |
Is MYMX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYMX income statement (TTM) | |
|---|---|
| Revenue | €533.00k |
| Cost of Revenue | €758.00k |
| Gross Profit | -€225.00k |
| Other Expenses | €11.34m |
| Earnings | -€11.57m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did MYMX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/25 00:02 |
| End of Day Share Price | 2025/12/12 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mymetics Corporation is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.